Key Objective
Initial public offer of 27,368,151* equity shares of face value of Rs. 2 each ("Equity Shares") of Akums Drugs and Pharmaceuticals Limited ("Company" or "Issuer") for cash at a price of Rs. 679^ per equity share (including a share premium of Rs. 677 per equity share) ("Offer Price") aggregating to
Rs. 1856.74 crores*^ comprising a fresh issue of 10,037,716* equity shares aggregating to Rs. 680.00*^ crores by the company ("Fresh Issue") and an offer for sale of 17,330,435 equity shares aggregating to Rs. 1176.74 crores* ("Offered Shares") by the selling shareholders, comprising of 1,512,000 equity shares aggregating to Rs. 102.67 crores* by Sanjeev Jain, 1,512,000 equity shares aggregating to Rs. 102.67 crores* by Sandeep Jain (together the "Promoter Selling Shareholders") and 14,306,435 equity shares aggregating to Rs. 971.41 crores* by Ruby QC Investment Holdings Pte. Ltd. (The "Investor Selling Shareholder") (the promoter selling shareholders and the investor selling shareholder, collectively referred to as the "Selling Shareholders") ("Offer for Sale", together with the fresh issue, the "Offer").
This offer includes a reservation of 243,902* equity shares aggregating to
Rs. 15.00 crores*^ for subscription by eligible employees (the "Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer constituted 17.39% and 17.23% of its post-offer paid-up equity share capital, respectively.
The face value of equity shares is Rs. 2 each. The offer price is 339.50 times the face value of the equity shares.
*Subject to finalization of basis of allotment
^After employee discount.